scholarly journals Continuous Exposure to Low-Dose Cisplatin and Apoptosis

2005 ◽  
Vol 28 (10) ◽  
pp. 1954-1957 ◽  
Author(s):  
Shuichi Kishimoto ◽  
Yuji Kawazoe ◽  
Mako Ikeno ◽  
Shoji Fukushima ◽  
Yoshikazu Takeuchi
Keyword(s):  
Low Dose ◽  
2012 ◽  
Vol 211 ◽  
pp. S159
Author(s):  
Sofiane Boudalia ◽  
Raymond Berges ◽  
Franck Menetrier ◽  
Cécile Helies ◽  
Marie-Chantal Canivenc-Lavier

2010 ◽  
Author(s):  
Jeyaprakash Jeyabalan ◽  
Pengxiao Cao ◽  
Manicka V. Vadhanam ◽  
Ramesh C. Gupta

2011 ◽  
Vol 24 (11) ◽  
pp. 1937-1943 ◽  
Author(s):  
Jeyaprakash Jeyabalan ◽  
Manicka V. Vadhanam ◽  
Srivani Ravoori ◽  
Ramesh C. Gupta

1986 ◽  
Vol 65 (12) ◽  
pp. 1415-1419 ◽  
Author(s):  
M.J. Vimy ◽  
A.J. Luft ◽  
F.L. Lorscheider

Estimated release rates of Hg vapor from dental amalgams permitted calculation of the potential Hg body burden by employing a four-compartment model for inorganic and elemental Hg distribution. A computer program, compatible with most personal computers, simulated the cumulative and incremental distribution in each compartment and total body accumulation between 1 and 10,000 days for different daily Hg dosages. For a given Hg dose of 30 μ g/day, metabolic compartments R1-R3 were close to equilibrium at 5, 100, and 300 days, respectively; whereas by 10,000 days, R4 closely approximated total body burden and had not yet attained equilibrium. Projected values obtained with the computer model were consistent with results obtained by another method using a standard tissue burden equation, which employed experimentally determined tissue half-lives for blood and CNS. The model predicted that continuous exposure to elemental Hg vapor, at 30 μ g/day for 10 years, would result in a total Hg body burden of 5.9 mg, of which 4.8 mg could be contained in R4. Assuming that the Hg in R4 displayed uniform distribution throughout the body, then the brain concentration was estimated to be 68 nglg wet weight. In contrast, if Hg in R4 reflected long-term preferential accumulation in brain and other neural tissue, then concentrations as high as 4.0 μ g/g could be attained. However, predictions of Hg concentrations in blood and urine were well within established ranges, and were unlikely to be of utility in assessing effects of chronic low-dose Hg exposure. It is concluded that the CNS could accumulate a substantial amount of Hg over extended time, based on low-dose elemental Hg vapor exposure via inhalation from dental amalgams.


2019 ◽  
Vol 51 (Supplement) ◽  
pp. 404 ◽  
Author(s):  
Walter Fj Schmidt ◽  
Torben Hoffmeister ◽  
Sandra Haupt ◽  
Nadine Wachsmuth ◽  
Dirk Schwenke ◽  
...  

Sarcoma ◽  
2013 ◽  
Vol 2013 ◽  
pp. 1-11 ◽  
Author(s):  
Jason E. Cain ◽  
Andrew McCaw ◽  
W. Samantha N. Jayasekara ◽  
Fernando J. Rossello ◽  
Kieren D. Marini ◽  
...  

Histone deacetylase inhibitors (HDACi) were identified nearly four decades ago based on their ability to induce cellular differentiation. However, the clinical development of these compounds as cancer therapies has focused on their capacity to induce apoptosis in hematologic and lymphoid malignancies, often in combination with conventional cytotoxic agents. In many cases, HDACi doses necessary to induce these effects result in significant toxicity. Since osteosarcoma cells express markers of terminal osteoblast differentiation in response to DNA methyltransferase inhibitors, we reasoned that the epigenetic reprogramming capacity of HDACi might be exploited for therapeutic benefit. Here, we show that continuous exposure of osteosarcoma cells to low concentrations of HDACi LBH589 (Panobinostat) over a three-week period induces terminal osteoblast differentiation and irreversible senescence without inducing cell death. Remarkably, transcriptional profiling revealed that HDACi therapy initiated gene signatures characteristic of chondrocyte and adipocyte lineages in addition to marked upregulation of mature osteoblast markers. In a mouse xenograft model, continuous low dose treatment with LBH589 induced a sustained cytostatic response accompanied by induction of mature osteoblast gene expression. These data suggest that the remarkable capacity of osteosarcoma cells to differentiate in response to HDACi therapy could be exploited for therapeutic benefit without inducing systemic toxicity.


Contraception ◽  
1991 ◽  
Vol 43 (4) ◽  
pp. 401-412 ◽  
Author(s):  
J.O. White ◽  
M.H.F Sullivan ◽  
L Patel ◽  
J.D. Croxtall ◽  
C. d'Arcangues ◽  
...  

PLoS ONE ◽  
2015 ◽  
Vol 10 (11) ◽  
pp. e0143403 ◽  
Author(s):  
Joong Sun Kim ◽  
Yeonghoon Son ◽  
Min Ji Bae ◽  
Seung Sook Lee ◽  
Sun Hoo Park ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document